Amsterdam Molecular Therapeutics Enters Research Collaboration with the University of Barcelona
News Feb 15, 2007
Amsterdam Molecular Therapeutics BV (AMT) has announced that it will undertake collaborative research activities in the area of gene regulation of fatty acid oxidation and obesity with the University of Barcelona, Spain.
The research group will be led by Professor Fausto G. Hegardt, Professor of Biochemistry and head of the Laboratory at the School of Pharmacy of the University of Barcelona.
The research will focus on development of a gene therapy capable of regulating mitochondrial fatty acid metabolism and insulin resistance.
The collaboration will initially aim to demonstrate the safety and efficacy of the product various preclinical models. If successful the product will be taken into clinical development and commercialization.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.